Ovarian cancer has several unique characteristics among adult solid tumors: the highest risk of thromboembolism from the disease burden itself and related treatments, survival benefit of extensive cytoreductive surgery to minimize residual tumor even in cases of peritoneal seeding, and the strongest hereditary portion in adult solid tumors.
than the surgical procedure itself while providing dual thromboprophylaxis consisting of gradient stockings and enoxaparin administration. The risk of thromboembolism should be carefully evaluated whenever there is suspicious ovarian cancer, and clinical suspicion is most important. Symptoms of thromboembolism such as dyspnea and/or leg edema can be easily ignored because ascites, pleural effusion, or lymphedema is commonly identified in ovarian cancer patients. Therefore, careful and objective evaluation is required for ovarian cancer patients with such symptoms.
In this issue, Kawaguchi et al. revealed that D-dimer level of <1.5 µg/mL may be used as the criteria to exclude the possibility of venous thromboembolism in a single center, retrospective study [4] . The sensitivity, specificity, positive predictive value, and negative predictive value are 100%, 62%, 33%, 100% if using cut-off value of D-dimer level >1.5 µg/mL. D-dimer is not expensive and very simple to evaluate. Because thromboembolism may result in a life-threatening event, early detection of thromboembolism is obviously very important. Prospective studies for subclinical detection of thromboembolism using D-dimer and/or thromboembolism-related symptoms are required to confirm the cost-effectiveness and/ or survival benefit. New recommendations on the guidelines of thromboembolism is required based on current evidence and results from future clinical trials.
